Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content.
Identifieur interne : 000214 ( Main/Exploration ); précédent : 000213; suivant : 000215Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content.
Auteurs : Fatma Beyazit [Turquie] ; Yavuz Beyazit [Turquie] ; Alpaslan Tanoglu [Turquie] ; Ibrahim C. Haznedaroglu [Turquie]Source :
- Medical hypotheses [ 1532-2777 ] ; 2020.
Descripteurs français
- KwdFr :
- Administration par voie topique (MeSH), Anti-inflammatoires (administration et posologie), Anti-inflammatoires (usage thérapeutique), Betacoronavirus (MeSH), Endothélium vasculaire (effets des médicaments et des substances chimiques), Extraits de plantes (administration et posologie), Extraits de plantes (composition chimique), Extraits de plantes (usage thérapeutique), Humains (MeSH), Hémostatiques (administration et posologie), Hémostatiques (usage thérapeutique), Infections à coronavirus (complications), Infections à coronavirus (sang), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (épidémiologie), Inflammation muqueuse (traitement médicamenteux), Inflammation muqueuse (étiologie), Oestrogènes (agonistes), Oestrogènes (physiologie), Pandémies (MeSH), Phyto-oestrogènes (administration et posologie), Phyto-oestrogènes (usage thérapeutique), Phytothérapie (MeSH), Pneumopathie virale (complications), Pneumopathie virale (sang), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (épidémiologie), Repositionnement des médicaments (MeSH), Récepteur de type PAR-1 (antagonistes et inhibiteurs), Récepteur de type PAR-1 (physiologie), Répartition par âge (MeSH), Stomatite (traitement médicamenteux), Stomatite (étiologie), Thrombophilie (sang), Thrombophilie (étiologie).
- MESH :
- administration et posologie : Anti-inflammatoires, Extraits de plantes, Hémostatiques, Phyto-oestrogènes.
- agonistes : Oestrogènes.
- antagonistes et inhibiteurs : Récepteur de type PAR-1.
- composition chimique : Extraits de plantes, Infections à coronavirus, Pneumopathie virale.
- effets des médicaments et des substances chimiques : Endothélium vasculaire.
- physiologie : Oestrogènes, Récepteur de type PAR-1.
- sang : Infections à coronavirus, Pneumopathie virale, Thrombophilie.
- traitement médicamenteux : Infections à coronavirus, Inflammation muqueuse, Pneumopathie virale, Stomatite.
- usage thérapeutique : Anti-inflammatoires, Extraits de plantes, Hémostatiques, Phyto-oestrogènes.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- étiologie : Inflammation muqueuse, Stomatite, Thrombophilie.
- Administration par voie topique, Betacoronavirus, Humains, Pandémies, Phytothérapie, Repositionnement des médicaments, Répartition par âge.
English descriptors
- KwdEn :
- Administration, Topical (MeSH), Age Distribution (MeSH), Anti-Inflammatory Agents (administration & dosage), Anti-Inflammatory Agents (therapeutic use), Betacoronavirus (MeSH), Coronavirus Infections (blood), Coronavirus Infections (complications), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Cytokine Release Syndrome (etiology), Cytokine Release Syndrome (physiopathology), Drug Repositioning (MeSH), Endothelium, Vascular (drug effects), Estrogens (agonists), Estrogens (physiology), Hemostatics (administration & dosage), Hemostatics (therapeutic use), Humans (MeSH), Mucositis (drug therapy), Mucositis (etiology), Pandemics (MeSH), Phytoestrogens (administration & dosage), Phytoestrogens (therapeutic use), Phytotherapy (MeSH), Plant Extracts (administration & dosage), Plant Extracts (chemistry), Plant Extracts (therapeutic use), Pneumonia, Viral (blood), Pneumonia, Viral (complications), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Receptor, PAR-1 (antagonists & inhibitors), Receptor, PAR-1 (physiology), Stomatitis (drug therapy), Stomatitis (etiology), Thrombophilia (blood), Thrombophilia (etiology).
- MESH :
- chemical , administration & dosage : Anti-Inflammatory Agents, Hemostatics, Phytoestrogens, Plant Extracts.
- chemical , agonists : Estrogens.
- chemical , antagonists & inhibitors : Receptor, PAR-1.
- chemical , chemistry : Plant Extracts.
- chemical , physiology : Estrogens, Receptor, PAR-1.
- chemical , therapeutic use : Anti-Inflammatory Agents, Hemostatics, Phytoestrogens, Plant Extracts.
- blood : Coronavirus Infections, Pneumonia, Viral, Thrombophilia.
- complications : Coronavirus Infections, Pneumonia, Viral.
- drug effects : Endothelium, Vascular.
- drug therapy : Coronavirus Infections, Mucositis, Pneumonia, Viral, Stomatitis.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- etiology : Cytokine Release Syndrome, Mucositis, Stomatitis, Thrombophilia.
- physiopathology : Cytokine Release Syndrome.
- Administration, Topical, Age Distribution, Betacoronavirus, Drug Repositioning, Humans, Pandemics, Phytotherapy.
Abstract
COVID-19 due to the SARS-CoV-2 infection is a multi-systemic immune syndrome affecting mainly the lungs, oropharyngeal region, and other vascular endothelial beds. There are tremendous ongoing efforts for the aim of developing drugs against the COVID-19 syndrome-associated inflammation. However, currently no specific medicine is present for the absolute pharmacological cure of COVID-19 mucositis. The re-purposing/re-positioning of already existing drugs is a very important strategy for the management of ongoing pandemy since the development of a new drug needs decades. Apart from altering angiotensin signaling pathways, novel drug candidates for re-purposing comprise medications shall target COVID-19 pathobiology, including pharmaceutical formulations that antagonize proteinase-activated receptors (PARs), mainly PAR-1. Activation of the PAR-1, mediators and hormones impact on the hemostasis, endothelial activation, alveolar epithelial cells and mucosal inflammatory responses which are the essentials of the COVID-19 pathophysiology. In this context, Ankaferd hemostat (Ankaferd Blood Stopper, ABS) which is an already approved hemostatic agent affecting via vital erythroid aggregation and fibrinogen gamma could be a potential topical remedy for the mucosal management of COVID-19. ABS is a clinically safe and effective topical hemostatic agent of plant origin capable of exerting pleiotropic effects on the endothelial cells, angiogenesis, cell proliferation and vascular dynamics. ABS had been approved as a topically applied hemostatic agent for the management of post-surgical/dental bleedings and healing of infected inflammatory mucosal wounds. The anti-inflammatory and proteinase-activated receptor axis properties of ABS with a considerable amount of oestrogenic hormone presence highlight this unique topical hemostatic drug regarding the clinical re-positioning for COVID-19-associated mucositis. Topical ABS as a biological response modifier may lessen SARS-CoV-2 associated microthrombosis, endothelial dysfunction, oropharyngeal inflammation and mucosal lung damage. Moreover, PAR-1 inhibition ability of ABS might be helpful for reducing the initial virus propagation and mocasal spread of COVID-19.
DOI: 10.1016/j.mehy.2020.110150
PubMed: 32763660
PubMed Central: PMC7392953
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content.</title><author><name sortKey="Beyazit, Fatma" sort="Beyazit, Fatma" uniqKey="Beyazit F" first="Fatma" last="Beyazit">Fatma Beyazit</name><affiliation wicri:level="1"><nlm:affiliation>Department of Obstetrics and Gynecology, Çanakkale Onsekiz Mart University, Çanakkale, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Obstetrics and Gynecology, Çanakkale Onsekiz Mart University, Çanakkale</wicri:regionArea><wicri:noRegion>Çanakkale</wicri:noRegion></affiliation></author><author><name sortKey="Beyazit, Yavuz" sort="Beyazit, Yavuz" uniqKey="Beyazit Y" first="Yavuz" last="Beyazit">Yavuz Beyazit</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gastroenterology, Çanakkale Onsekiz Mart University, Çanakkale, Turkey. Electronic address: yavuzbeyazit@comu.edu.tr.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Gastroenterology, Çanakkale Onsekiz Mart University, Çanakkale</wicri:regionArea><wicri:noRegion>Çanakkale</wicri:noRegion></affiliation></author><author><name sortKey="Tanoglu, Alpaslan" sort="Tanoglu, Alpaslan" uniqKey="Tanoglu A" first="Alpaslan" last="Tanoglu">Alpaslan Tanoglu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gastroenterology, Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Gastroenterology, Sultan Abdulhamid Han Training and Research Hospital, Istanbul</wicri:regionArea><wicri:noRegion>Istanbul</wicri:noRegion></affiliation></author><author><name sortKey="Haznedaroglu, Ibrahim C" sort="Haznedaroglu, Ibrahim C" uniqKey="Haznedaroglu I" first="Ibrahim C" last="Haznedaroglu">Ibrahim C. Haznedaroglu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Hacettepe University Faculty of Medicine, Ankara, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Hematology, Hacettepe University Faculty of Medicine, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32763660</idno><idno type="pmid">32763660</idno><idno type="doi">10.1016/j.mehy.2020.110150</idno><idno type="pmc">PMC7392953</idno><idno type="wicri:Area/Main/Corpus">000075</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000075</idno><idno type="wicri:Area/Main/Curation">000075</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000075</idno><idno type="wicri:Area/Main/Exploration">000075</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content.</title><author><name sortKey="Beyazit, Fatma" sort="Beyazit, Fatma" uniqKey="Beyazit F" first="Fatma" last="Beyazit">Fatma Beyazit</name><affiliation wicri:level="1"><nlm:affiliation>Department of Obstetrics and Gynecology, Çanakkale Onsekiz Mart University, Çanakkale, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Obstetrics and Gynecology, Çanakkale Onsekiz Mart University, Çanakkale</wicri:regionArea><wicri:noRegion>Çanakkale</wicri:noRegion></affiliation></author><author><name sortKey="Beyazit, Yavuz" sort="Beyazit, Yavuz" uniqKey="Beyazit Y" first="Yavuz" last="Beyazit">Yavuz Beyazit</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gastroenterology, Çanakkale Onsekiz Mart University, Çanakkale, Turkey. Electronic address: yavuzbeyazit@comu.edu.tr.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Gastroenterology, Çanakkale Onsekiz Mart University, Çanakkale</wicri:regionArea><wicri:noRegion>Çanakkale</wicri:noRegion></affiliation></author><author><name sortKey="Tanoglu, Alpaslan" sort="Tanoglu, Alpaslan" uniqKey="Tanoglu A" first="Alpaslan" last="Tanoglu">Alpaslan Tanoglu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gastroenterology, Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Gastroenterology, Sultan Abdulhamid Han Training and Research Hospital, Istanbul</wicri:regionArea><wicri:noRegion>Istanbul</wicri:noRegion></affiliation></author><author><name sortKey="Haznedaroglu, Ibrahim C" sort="Haznedaroglu, Ibrahim C" uniqKey="Haznedaroglu I" first="Ibrahim C" last="Haznedaroglu">Ibrahim C. Haznedaroglu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Hacettepe University Faculty of Medicine, Ankara, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Hematology, Hacettepe University Faculty of Medicine, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author></analytic><series><title level="j">Medical hypotheses</title><idno type="eISSN">1532-2777</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Topical (MeSH)</term><term>Age Distribution (MeSH)</term><term>Anti-Inflammatory Agents (administration & dosage)</term><term>Anti-Inflammatory Agents (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>Coronavirus Infections (blood)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Cytokine Release Syndrome (etiology)</term><term>Cytokine Release Syndrome (physiopathology)</term><term>Drug Repositioning (MeSH)</term><term>Endothelium, Vascular (drug effects)</term><term>Estrogens (agonists)</term><term>Estrogens (physiology)</term><term>Hemostatics (administration & dosage)</term><term>Hemostatics (therapeutic use)</term><term>Humans (MeSH)</term><term>Mucositis (drug therapy)</term><term>Mucositis (etiology)</term><term>Pandemics (MeSH)</term><term>Phytoestrogens (administration & dosage)</term><term>Phytoestrogens (therapeutic use)</term><term>Phytotherapy (MeSH)</term><term>Plant Extracts (administration & dosage)</term><term>Plant Extracts (chemistry)</term><term>Plant Extracts (therapeutic use)</term><term>Pneumonia, Viral (blood)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (epidemiology)</term><term>Receptor, PAR-1 (antagonists & inhibitors)</term><term>Receptor, PAR-1 (physiology)</term><term>Stomatitis (drug therapy)</term><term>Stomatitis (etiology)</term><term>Thrombophilia (blood)</term><term>Thrombophilia (etiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie topique (MeSH)</term><term>Anti-inflammatoires (administration et posologie)</term><term>Anti-inflammatoires (usage thérapeutique)</term><term>Betacoronavirus (MeSH)</term><term>Endothélium vasculaire (effets des médicaments et des substances chimiques)</term><term>Extraits de plantes (administration et posologie)</term><term>Extraits de plantes (composition chimique)</term><term>Extraits de plantes (usage thérapeutique)</term><term>Humains (MeSH)</term><term>Hémostatiques (administration et posologie)</term><term>Hémostatiques (usage thérapeutique)</term><term>Infections à coronavirus (complications)</term><term>Infections à coronavirus (sang)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (épidémiologie)</term><term>Inflammation muqueuse (traitement médicamenteux)</term><term>Inflammation muqueuse (étiologie)</term><term>Oestrogènes (agonistes)</term><term>Oestrogènes (physiologie)</term><term>Pandémies (MeSH)</term><term>Phyto-oestrogènes (administration et posologie)</term><term>Phyto-oestrogènes (usage thérapeutique)</term><term>Phytothérapie (MeSH)</term><term>Pneumopathie virale (complications)</term><term>Pneumopathie virale (sang)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (épidémiologie)</term><term>Repositionnement des médicaments (MeSH)</term><term>Récepteur de type PAR-1 (antagonistes et inhibiteurs)</term><term>Récepteur de type PAR-1 (physiologie)</term><term>Répartition par âge (MeSH)</term><term>Stomatite (traitement médicamenteux)</term><term>Stomatite (étiologie)</term><term>Thrombophilie (sang)</term><term>Thrombophilie (étiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Inflammatory Agents</term><term>Hemostatics</term><term>Phytoestrogens</term><term>Plant Extracts</term></keywords><keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en"><term>Estrogens</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptor, PAR-1</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Plant Extracts</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Estrogens</term><term>Receptor, PAR-1</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Inflammatory Agents</term><term>Hemostatics</term><term>Phytoestrogens</term><term>Plant Extracts</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anti-inflammatoires</term><term>Extraits de plantes</term><term>Hémostatiques</term><term>Phyto-oestrogènes</term></keywords><keywords scheme="MESH" qualifier="agonistes" xml:lang="fr"><term>Oestrogènes</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Récepteur de type PAR-1</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Thrombophilia</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="composition chimique" xml:lang="fr"><term>Extraits de plantes</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Endothelium, Vascular</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Mucositis</term><term>Pneumonia, Viral</term><term>Stomatitis</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Endothélium vasculaire</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cytokine Release Syndrome</term><term>Mucositis</term><term>Stomatitis</term><term>Thrombophilia</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Oestrogènes</term><term>Récepteur de type PAR-1</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Cytokine Release Syndrome</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term><term>Thrombophilie</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Inflammation muqueuse</term><term>Pneumopathie virale</term><term>Stomatite</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anti-inflammatoires</term><term>Extraits de plantes</term><term>Hémostatiques</term><term>Phyto-oestrogènes</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Inflammation muqueuse</term><term>Stomatite</term><term>Thrombophilie</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Topical</term><term>Age Distribution</term><term>Betacoronavirus</term><term>Drug Repositioning</term><term>Humans</term><term>Pandemics</term><term>Phytotherapy</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie topique</term><term>Betacoronavirus</term><term>Humains</term><term>Pandémies</term><term>Phytothérapie</term><term>Repositionnement des médicaments</term><term>Répartition par âge</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">COVID-19 due to the SARS-CoV-2 infection is a multi-systemic immune syndrome affecting mainly the lungs, oropharyngeal region, and other vascular endothelial beds. There are tremendous ongoing efforts for the aim of developing drugs against the COVID-19 syndrome-associated inflammation. However, currently no specific medicine is present for the absolute pharmacological cure of COVID-19 mucositis. The re-purposing/re-positioning of already existing drugs is a very important strategy for the management of ongoing pandemy since the development of a new drug needs decades. Apart from altering angiotensin signaling pathways, novel drug candidates for re-purposing comprise medications shall target COVID-19 pathobiology, including pharmaceutical formulations that antagonize proteinase-activated receptors (PARs), mainly PAR-1. Activation of the PAR-1, mediators and hormones impact on the hemostasis, endothelial activation, alveolar epithelial cells and mucosal inflammatory responses which are the essentials of the COVID-19 pathophysiology. In this context, Ankaferd hemostat (Ankaferd Blood Stopper, ABS) which is an already approved hemostatic agent affecting via vital erythroid aggregation and fibrinogen gamma could be a potential topical remedy for the mucosal management of COVID-19. ABS is a clinically safe and effective topical hemostatic agent of plant origin capable of exerting pleiotropic effects on the endothelial cells, angiogenesis, cell proliferation and vascular dynamics. ABS had been approved as a topically applied hemostatic agent for the management of post-surgical/dental bleedings and healing of infected inflammatory mucosal wounds. The anti-inflammatory and proteinase-activated receptor axis properties of ABS with a considerable amount of oestrogenic hormone presence highlight this unique topical hemostatic drug regarding the clinical re-positioning for COVID-19-associated mucositis. Topical ABS as a biological response modifier may lessen SARS-CoV-2 associated microthrombosis, endothelial dysfunction, oropharyngeal inflammation and mucosal lung damage. Moreover, PAR-1 inhibition ability of ABS might be helpful for reducing the initial virus propagation and mocasal spread of COVID-19.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32763660</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2777</ISSN><JournalIssue CitedMedium="Internet"><Volume>143</Volume><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Medical hypotheses</Title><ISOAbbreviation>Med Hypotheses</ISOAbbreviation></Journal><ArticleTitle>Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content.</ArticleTitle><Pagination><MedlinePgn>110150</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0306-9877(20)32186-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mehy.2020.110150</ELocationID><Abstract><AbstractText>COVID-19 due to the SARS-CoV-2 infection is a multi-systemic immune syndrome affecting mainly the lungs, oropharyngeal region, and other vascular endothelial beds. There are tremendous ongoing efforts for the aim of developing drugs against the COVID-19 syndrome-associated inflammation. However, currently no specific medicine is present for the absolute pharmacological cure of COVID-19 mucositis. The re-purposing/re-positioning of already existing drugs is a very important strategy for the management of ongoing pandemy since the development of a new drug needs decades. Apart from altering angiotensin signaling pathways, novel drug candidates for re-purposing comprise medications shall target COVID-19 pathobiology, including pharmaceutical formulations that antagonize proteinase-activated receptors (PARs), mainly PAR-1. Activation of the PAR-1, mediators and hormones impact on the hemostasis, endothelial activation, alveolar epithelial cells and mucosal inflammatory responses which are the essentials of the COVID-19 pathophysiology. In this context, Ankaferd hemostat (Ankaferd Blood Stopper, ABS) which is an already approved hemostatic agent affecting via vital erythroid aggregation and fibrinogen gamma could be a potential topical remedy for the mucosal management of COVID-19. ABS is a clinically safe and effective topical hemostatic agent of plant origin capable of exerting pleiotropic effects on the endothelial cells, angiogenesis, cell proliferation and vascular dynamics. ABS had been approved as a topically applied hemostatic agent for the management of post-surgical/dental bleedings and healing of infected inflammatory mucosal wounds. The anti-inflammatory and proteinase-activated receptor axis properties of ABS with a considerable amount of oestrogenic hormone presence highlight this unique topical hemostatic drug regarding the clinical re-positioning for COVID-19-associated mucositis. Topical ABS as a biological response modifier may lessen SARS-CoV-2 associated microthrombosis, endothelial dysfunction, oropharyngeal inflammation and mucosal lung damage. Moreover, PAR-1 inhibition ability of ABS might be helpful for reducing the initial virus propagation and mocasal spread of COVID-19.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beyazit</LastName><ForeName>Fatma</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Çanakkale Onsekiz Mart University, Çanakkale, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beyazit</LastName><ForeName>Yavuz</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Çanakkale Onsekiz Mart University, Çanakkale, Turkey. Electronic address: yavuzbeyazit@comu.edu.tr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanoglu</LastName><ForeName>Alpaslan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haznedaroglu</LastName><ForeName>Ibrahim C</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hacettepe University Faculty of Medicine, Ankara, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Hypotheses</MedlineTA><NlmUniqueID>7505668</NlmUniqueID><ISSNLinking>0306-9877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004967">Estrogens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006490">Hemostatics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048789">Phytoestrogens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044463">Receptor, PAR-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C539751">ankaferd blood stopper</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000287" MajorTopicYN="N">Administration, Topical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004967" MajorTopicYN="N">Estrogens</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006490" MajorTopicYN="N">Hemostatics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052016" MajorTopicYN="N">Mucositis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048789" MajorTopicYN="N">Phytoestrogens</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008517" MajorTopicYN="Y">Phytotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044463" MajorTopicYN="N">Receptor, PAR-1</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013280" MajorTopicYN="N">Stomatitis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019851" MajorTopicYN="N">Thrombophilia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ankaferd hemostat</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Oestrogen</Keyword><Keyword MajorTopicYN="N">PAR-1</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>07</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32763660</ArticleId><ArticleId IdType="pii">S0306-9877(20)32186-1</ArticleId><ArticleId IdType="doi">10.1016/j.mehy.2020.110150</ArticleId><ArticleId IdType="pmc">PMC7392953</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Turquie</li></country></list><tree><country name="Turquie"><noRegion><name sortKey="Beyazit, Fatma" sort="Beyazit, Fatma" uniqKey="Beyazit F" first="Fatma" last="Beyazit">Fatma Beyazit</name></noRegion><name sortKey="Beyazit, Yavuz" sort="Beyazit, Yavuz" uniqKey="Beyazit Y" first="Yavuz" last="Beyazit">Yavuz Beyazit</name><name sortKey="Haznedaroglu, Ibrahim C" sort="Haznedaroglu, Ibrahim C" uniqKey="Haznedaroglu I" first="Ibrahim C" last="Haznedaroglu">Ibrahim C. Haznedaroglu</name><name sortKey="Tanoglu, Alpaslan" sort="Tanoglu, Alpaslan" uniqKey="Tanoglu A" first="Alpaslan" last="Tanoglu">Alpaslan Tanoglu</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PlantImRecepV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000214 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000214 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PlantImRecepV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32763660
|texte= Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32763660" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PlantImRecepV1
| This area was generated with Dilib version V0.6.38. |  |